

# Xiaoyan Chu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10223589/publications.pdf>

Version: 2024-02-01

19  
papers

3,802  
citations

567144

15  
h-index

794469

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

4145  
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	21.5	2,886
2	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	2.3	141
3	Variability in P-Glycoprotein Inhibitory Potency ( $IC_{50}$ ) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1347-1366.	1.7	136
4	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1752-1758.	1.7	100
5	Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>In Vitro</i> , Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 865-889.	2.3	92
6	Physiologically Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1082-1115.	2.3	88
7	Positron Emission Tomography Imaging of [ <sup>11</sup> C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1056-1066.	2.3	51
8	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	1.7	43
9	Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1367-1374.	1.7	41
10	A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 350-357.	1.7	37
11	Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 788-792.	2.3	32
12	A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 403-415.	2.3	31
13	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. <i>Drug Metabolism and Disposition</i> , 2021, 49, 159-168.	1.7	24
14	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. <i>Molecular Pharmacology</i> , 2016, 89, 492-504.	1.0	23
15	Clinical Implications of Altered Drug Transporter Abundance/Function and PBP Modeling in Specific Populations: An ITC Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	2.3	21
16	Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1315-1323.	2.3	16
17	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 540-561.	2.3	16
18	Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 573-592.	2.3	15

#	ARTICLE	IF	CITATIONS
19	Coproporphyrin I as an Endogenous Biomarker to Detect Reduced <sc>OATP1B</sc> Activity and Shift in Elimination Route in Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 615-626.	2.3	9